Contraceptive Development Program efforts focus on development of new methods of contraception for women and men.
NICHD has been leading federal research efforts on contraception since shortly after its establishment, when the Secretary of Health Education and Welfare established the Center for Population Research within the institute. Later, the Contraceptive Development Branch was created with the goal of developing new contraceptive methods. In 2017, the CDP was established in DIPHR with the mission to advance clinical development of novel contraceptive methods for men and women.
CDP uses contract mechanisms to pursue this goal, supporting a Chemical Synthesis Facility to synthesize clinical grade, active pharmaceutical ingredients that are not commercially available; a Biological Testing Facility that performs preclinical testing to qualify agents for studies approved by the U.S. Food and Drug Administration (FDA); and Contraceptive Clinical Trials Network, which conducts clinical evaluation of new contraceptives for males and females. CDP scientists coordinate and integrate program components to produce groundbreaking contraceptive research. The program also utilizes technology transfer mechanisms to form partnerships, translating discoveries and clinical advances into products that address unmet contraceptive needs of men and women.
Interview with Dr. Blithe (MP4 67 MB) at the 15th Congress of the European Society of Contraception and Reproductive Health